Key facts
- It has raised $50.3M across 2 recorded rounds; the latest was Early Stage VC ($6.2M) in Jun 2025.
- Notable investors include Dhuna Ventures, Florida Opportunity Fund, MintPharma Capital, One One Five Group of Companies, Purchase Capital.
- PleoPharma has filed 3 Form Ds with the SEC since 2020, most recently Aug 2025 ($6.2M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for PleoPharma
Funding rounds
2 roundsAbout PleoPharma
Operator of a pharmaceutical company intended to develop a treatment that helps meet the growing demand of an unmet and significant medical condition. The company specializes in minimizing barriers by designing therapy and to address unmet and growing needs in the central nervous system and substance abuse space, enabling patients to receive effective medical treatment and improving their health status.
- Sector
- Healthcare
- HQ
- Phoenixville, PA, United States
- Founded
- 2019
- Employees
- 8
- Website
- pleopharma.com/
- Ownership
- Privately Held (backing)
PleoPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PleoPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PleoPharma in its N-PORT filings yet. We sweep new filings monthly.